Quality of Care for Chronic Illness in Primary Care:  Opportunities for Improvement in Process and Outcome Measures

Steven M. Ornstein, MD;Ruth G. Jenkins, MS;

Publication

Article

May 1, 1999

The American Journal of Managed Care

May 1999

Volume 5

Issue 5

Quality of Care for Chronic Illness in Primary Care: Opportunities for Improvement in Process and Outcome Measures

Author(s):

Steven M. Ornstein, MDRuth G. Jenkins, MS

Download PDF: Quality of Care for Chronic Illness in Primary Care: Opportunities for Improvement in Process and Outcome Measures

Articles in this issue

Relationship between Primary Payer and Use of Proactive Immunization Practices: A National Survey

Polypharmacy Management in Medicare Managed Care: Changes in Prescribing by Primary Care Physicians Resulting from a Program Promoting Medication Reviews

Course and Cost of Treatment for Depression with Fluoxetine, Paroxetine, and Sertraline

Project LEAP of New Jersey: Lower Extremity Amputation Prevention in Persons with Type 2 Diabetes

Quality of Care for Chronic Illness in Primary Care: Opportunities for Improvement in Process and Outcome Measures

Assessment of Patient Satisfaction with a Formulary Switch from Omeprazole to Lansoprazole in Gastroesophageal Reflux Disease Maintenance Therapy

Overview of Platelet Glycoprotein IIb/IIIa Receptor Antagonist Treatment in the Management of Coronary Interventions and Acute Ischemic Coronary Syndromes

Benign Prostatic Hyperplasia: An Overview for Pharmacists

Correspondence regarding, "How Should Managed Care Treat Onychomycosis?"

Related Content

October 8th 2024

Teamwork Enhances Patient Experience: Linking TEAM and Net Promoter Scores

Amy Nguyen Howell, MD Jacqueline Ruffing, MHA Omid Ameli, MD, DrPH Christine E. Chaisson, MPH Dawn Webster, MPAS, PA-C Sara Poplau, BA Erin Sullivan, PhD Martin Stillman, MD, JD Mark Linzer, MD

In 1386 providers, better teamwork related to higher patient Net Promoter Score (NPS), and the relationship between provider experience and NPS was mediated by teamwork.

October 7th 2024

The Price of Progress: Understanding Innovation and Affordability of Prescription Drugs

Anthony T. Lo Sasso, PhD M. Christopher Roebuck, PhD

Economic incentives and patent protections drive development of innovative medications. Drug prices are determined by consumer demand, not production costs. Therefore, governmental regulation risks future investment in research and development.

October 2nd 2024

Implementation of Two Guideline-Based Pilot Programs for Patients With ASCVD: Strategies and Perspectives

September 20th 2024

Systemic Treatments for Advanced Prostate Cancer: Relationship Between Health Insurance Plan and Treatment Costs

Deborah R. Kaye, MD, MS Hui-Jie Lee, PhD Alexander Gordee, MA Daniel J. George, MD Charles D. Scales Jr, MD, MSHS Peter A. Ubel, MD M. Kate Bundorf, PhD, MBA, MPH

The authors examine how insurer and patient out-of-pocket payments for advanced prostate cancer differ by drug and health plan type and describe the relationship between these payments and utilization.

September 19th 2024

Care Transition Management and Patient Outcomes in Hospitalized Medicare Beneficiaries

Mariétou H. Ouayogodé, PhD Brianna Hardy, BS John Mullahy, PhD Maureen A. Smith, MD, PhD, MPH Ellen Meara, PhD

Hospital care transition activity facilitates uptake of Medicare-reimbursed transitional care management, which is associated with lower spending and better patient outcomes.

September 18th 2024

COPD Treatment Ratio: A Measure for Improving COPD Population Health

Megha A. Parikh, PhD, MS Sabree C. Burbage, PharmD, MPH Meghan H. Gabriel, PhD Ben E. Shirley, BSPH Patrick J. Campbell, PharmD, PhD

This article supports the use of the chronic obstructive pulmonary disease (COPD) treatment ratio as a surrogate marker of COPD exacerbation risk for quality measurement purposes.